Manipal Health Enterprises Limited (MANIPALHOS)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Manipal Health's revenue was ₹1,048 Cr (+28.2% year on year, +8.4% on the previous quarter), and net profit ₹116 Cr (-8.3% year on year); the operating margin was 23.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1,048 | +28.2% | +8.4% |
| Operating profit | ₹250 | +12.1% | +12.1% |
| Net profit | ₹116 | -8.3% | +25.6% |
| EPS (₹) | 0.98 | -10.1% | +25.6% |
| Operating margin | 23.9% | — | — |
MANIPALHOS delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 42.77% of the MANIPALHOS shares traded on NSE were taken to delivery, against the stock's own 20-session average of 50.42%. That is lower than usual for this stock. Volume was 0.3 times its average, well below normal.
Delivery in the last 5 sessions: 50.2% · 44.2% · 47.6% · 40.5% · 42.8%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Manipal Health Enterprises Limited concluded its 16th AGM on September 29, 2026, where 10 of 11 proposed resolutions were approved by shareholders. Notably, Resolution 9 regarding an Upside Sharing Arrangement between Manipal Research & Management Services International and TPG SG Magazine Pte. Ltd. was defeated, receiving 61.99% votes against (6,68,85,785 votes against vs 4,10,16,249 in favour). Other key proposals passed, including Price Waterhouse Chartered Accountants LLP's appointment as statutory auditor (99.99% approval) and special governance rights under the Articles of Association for Temasek and MGHS Groups (94.45% approval).
- 10 out of 11 resolutions approved at the 16th AGM held on September 29, 2026
- Resolution 9 (Upside Sharing Arrangement with TPG) rejected with 61.9875% votes cast against
- PwC appointed as statutory auditor with 99.9999% votes in favour (1,20,18,09,921 votes)
- Amendments to Articles of Association granting rights to Temasek and MGHS Groups passed with 94.4546% approval
- Total voter turnout represented 91.3663% of outstanding shares (1,20,18,10,823 votes polled)
Manipal Health Enterprises Limited reported the proceedings of its 16th Annual General Meeting held on September 29, 2026. The Chairman highlighted FY26 revenue growth of 25.4% to ₹10,336 crores, with operating EBITDA of ₹2,644 crores (25.6% margin) and PAT of ₹917 crores. The network expanded to 49 hospitals with over 13,000 licensed beds, supported by the Sahyadri Hospitals acquisition (10 hospitals, 1,606 beds) and two new greenfield Bengaluru facilities. A total of 11 resolutions—including ESOP 2024 ratification, auditor appointments, and governance rights for Temasek and MGHS Groups—were tabled for voting.
- FY26 revenue increased 25.4% YoY to ₹10,336 crores, compared to ₹8,242 crores in the previous year
- Operating EBITDA reached ₹2,644 crores at a 25.6% margin, while PAT stood at ₹917 crores
- Operated 49 hospitals with >13,000 licensed beds across 14 States/UTs as of March 31, 2026
- Sahyadri Hospitals acquisition added 10 hospitals and 1,606 licensed beds
- Shareholders voted on 11 resolutions including ESOP 2024 and special nomination rights to Temasek and MGHS Groups
Manipal Health Enterprises Limited reported the proceedings of its 16th Annual General Meeting held on September 29, 2026. The Chairman highlighted FY26 revenue growth of 25.4% to ₹10,336 crores, with operating EBITDA of ₹2,644 crores (25.6% margin) and PAT of ₹917 crores. The network expanded to 49 hospitals with over 13,000 licensed beds, supported by the Sahyadri Hospitals acquisition (10 hospitals, 1,606 beds) and two new greenfield Bengaluru facilities. A total of 11 resolutions—including ESOP 2024 ratification, auditor appointments, and governance rights for Temasek and MGHS Groups—were tabled for voting.
- FY26 revenue increased 25.4% YoY to ₹10,336 crores, compared to ₹8,242 crores in the previous year
- Operating EBITDA reached ₹2,644 crores at a 25.6% margin, while PAT stood at ₹917 crores
- Operated 49 hospitals with >13,000 licensed beds across 14 States/UTs as of March 31, 2026
- Sahyadri Hospitals acquisition added 10 hospitals and 1,606 licensed beds
- Shareholders voted on 11 resolutions including ESOP 2024 and special nomination rights to Temasek and MGHS Groups
Manipal Health Enterprises Limited has fully redeemed outstanding listed Non-Convertible Debentures (NCDs) worth ₹5,310 crore issued by its subsidiary, Manipal Hospitals Private Limited, utilizing its IPO proceeds. The redemption covers principal, accrued interest, and early redemption costs in accordance with its July 31, 2026 prospectus objects. This debt reduction is aimed at significantly strengthening the balance sheet and lowering future interest burdens. In Q1 FY27, the company reported consolidated revenue growth of 38.1% year-on-year to ₹3,091 crore and an EBITDA of ₹749 crore.
- Full redemption of outstanding listed NCDs with nominal value of ₹5,310 crore
- Funded via IPO proceeds in line with the prospectus dated July 31, 2026
- Q1 FY27 revenue stood at ₹3,091 crore (up 38.1% YoY) with EBITDA at ₹749 crore (up 26.4% YoY)
- Q1 FY27 PAT reported at ₹243 crore, with adjusted PAT reaching ₹332 crore
Manipal Health Enterprises Limited has fully redeemed outstanding listed non-convertible debentures (NCDs) worth Rs 5,310 crore issued by its wholly owned subsidiary, Manipal Hospitals Private Limited. The redemption, which includes accrued interest and early prepayment charges, was funded using the proceeds from its recent Initial Public Offering. This utilization aligns with the stated objects of the offer outlined in its Prospectus dated July 31, 2026. The full repayment significantly deleverages the consolidated balance sheet.
- Full redemption of Rs 5,310 crore nominal value listed NCDs issued by subsidiary Manipal Hospitals Private Limited
- Funded via relevant portion of proceeds raised through the company's Initial Public Offering
- Redemption includes nominal value, accrued interest, and applicable early prepayment costs
- Executed strictly as per the objects of the offer detailed in the Prospectus dated July 31, 2026
Manipal Health Enterprises Limited has issued a communication under Regulation 36(1)(b) of SEBI LODR providing the weblink to its Annual Report for FY 2025-26 and the Notice of its 16th Annual General Meeting (AGM). The AGM is scheduled to take place on Tuesday, September 29, 2026, at 11:00 a.m. IST via Video Conferencing / Other Audio-Visual Means. The physical dispatch of the weblink is directed to shareholders whose email addresses are not registered with the company or depository participants.
- 16th Annual General Meeting scheduled for Tuesday, September 29, 2026, at 11:00 a.m. IST
- AGM to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM)
- Annual Report for FY 2025-26 and AGM notice made available on the company website and exchange portals
- Communication dispatched to unregistered shareholders via RTA KFin Technologies Limited
Manipal Health Enterprises released the transcript of its Q1 FY27 earnings call, reporting consolidated revenue of ₹3,091 crore, up over 38% YoY. Network EBITDA reached ₹749 crore (+26% YoY) with an operating margin of 24.2% (25% excluding Sahyadri Hospitals). Growth was driven by a 39% rise in inpatient volumes and 26% in OP volumes, with network occupancy at 65% and ALOS at 2.7 days. The company has expanded its network to over 13,000 beds, launched its 50th hospital in Bangalore, and maintains a low net debt-to-EBITDA ratio of 0.9x post-IPO.
- Q1 revenue grew 38% YoY to ₹3,091 crore with Network EBITDA reaching ₹749 crore (24.2% margin)
- ARPOB ex-Sahyadri rose 9% YoY to ₹77,200/day, with network occupancy improving by 290 bps to 65%
- Sahyadri Hospitals delivered ₹332 crore in revenue and ₹58 crore EBITDA (17% margin vs 25% ex-Sahyadri)
- Digital revenue contributed ₹710 crore, accounting for 23% of total revenue in Q1
- Total network capacity stands above 13,000 beds following 103 brownfield beds in Nashik and a new 300-bed unit in Electronic City
Manipal Health Enterprises Limited has published the audio recording of its earnings conference call conducted with analysts and institutional investors on August 21, 2026, at 11:00 AM. The recording has been uploaded on the company's website in compliance with SEBI LODR Regulations 30 and 46. In the preceding June 2026 quarter, the company reported revenue of ₹1,048.30 cr and net profit of ₹115.53 cr.
- Earnings conference call with analysts and investors conducted on August 21, 2026 at 11:00 AM
- Audio recording uploaded to the company website pursuant to SEBI LODR Regulations 30 and 46
- Company posted revenue of ₹1,048.30 cr and operating profit of ₹250.05 cr in the Jun 2026 quarter
Manipal Health Enterprises has approved the appointment of Price Waterhouse Chartered Accountants LLP as its statutory auditor for a 5-year tenure (FY27 to FY31), succeeding BSR & Co. LLP upon tenure completion. The Board also approved amendments to the Articles of Association granting Temasek Group right to nominate up to 3 directors and MGHS Group up to 2 directors, provided each holds at least 6% equity. Additionally, the Board noted an upside sharing payment between TPG and promoter entity MRMSI, subject to shareholder approval at the AGM scheduled for September 29, 2026.
- Appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term from the 16th AGM to 21st AGM.
- AoA amendment enabling Temasek Group to nominate up to 3 Directors and 3 Executive Committee members subject to a minimum 6% holding.
- AoA amendment enabling MGHS Group to nominate up to 2 Directors and 2 Executive Committee members subject to a minimum 6% holding.
- Noted upside share amount payable by TPG to promoter group entity MRMSI under March 16, 2026 agreement, subject to Reg 26(6) shareholder approval.
- 16th Annual General Meeting scheduled for September 29, 2026.
Manipal Health Enterprises reported a 38.1% YoY increase in revenue from operations to ₹3,091 crore for Q1 FY27 in its first earnings report post-listing. EBITDA grew 26.4% YoY to ₹749 crore with a 24.2% margin (adjusted EBITDA up 29.7% YoY). Reported PAT stood at ₹243 crore, while PAT adjusted for ₹89 crore post-tax interest on Sahyadri acquisition NCDs rose 30.9% YoY to ₹332 crore. Network occupancy improved by 290 bps YoY to 65.0%, and ARPOB (excluding Sahyadri) grew 8.7% YoY to ₹77,200 per day.
- Revenue from operations grew 38.1% YoY to ₹3,091 crore in Q1 FY27 compared to ₹2,238 crore in Q1 FY26.
- EBITDA increased 26.4% YoY to ₹749 crore; adjusted EBITDA (ex-one-off) grew 29.7% YoY.
- Adjusted PAT reached ₹332 crore (up 30.9% YoY), excluding ₹89 crore post-tax interest on Sahyadri NCD debt.
- Occupancy expanded 290 bps YoY to 65.0%, with inpatient volumes up 38.8% YoY.
- Sahyadri Hospitals contributed ₹332 crore in revenue (+12.8% YoY) and ₹58 crore in EBITDA (+18.7% YoY).
In its maiden quarterly results post-listing, Manipal Health Enterprises reported a 38.1% YoY increase in consolidated revenue from operations to ₹3,091 crore for Q1 FY27. EBITDA grew 26.4% YoY to ₹749 crore, with adjusted EBITDA growing 29.7% YoY excluding a one-off gain in the base quarter. Reported PAT was ₹243 crore, while PAT adjusted for ₹89 crore post-tax interest on NCDs for the Sahyadri acquisition rose 30.9% YoY to ₹332 crore. Network occupancy improved by 290 bps YoY to 65.0%, supported by a 38.8% growth in inpatient volumes.
- Revenue from operations grew 38.1% YoY to ₹3,091 crore in Q1 FY27
- EBITDA increased 26.4% YoY to ₹749 crore; adjusted EBITDA up 29.7% YoY
- Reported PAT stood at ₹243 crore; adjusted PAT rose 30.9% YoY to ₹332 crore (ex-Sahyadri acquisition debt interest)
- ARPOB excluding Sahyadri increased 8.7% YoY to ₹77,200 per day
- Consolidated network occupancy improved 290 bps YoY to 65.0%
Manipal Health Enterprises Limited's Board approved the appointment of M/s Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term from FY 2026-27 to FY 2030-31 (16th AGM to 21st AGM), replacing M/s BSR & Co. LLP upon tenure completion. The Board also approved amendments to the Articles of Association (AoA) granting Temasek Group (up to 3 nominees) and MGHS Group (up to 2 nominees) board and executive committee nomination rights subject to maintaining at least 6% equity shareholding. Additionally, the 16th AGM is scheduled for September 29, 2026, where shareholder approval will also be sought for an upside sharing agreement between TPG and promoter entity MRMSI under SEBI LODR Regulation 26(6).
- Appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for 5 consecutive years (FY 2026-27 to FY 2030-31)
- AoA amendment grants Temasek Group right to nominate up to 3 directors while holding at least 6% equity
- MGHS Group granted right to nominate up to 2 directors while holding at least 6% equity
- 16th Annual General Meeting scheduled for September 29, 2026 via video conferencing
- Noted upside share payment from TPG to promoter entity MRMSI per March 16, 2026 agreement, subject to shareholder approval
Manipal Health Enterprises Limited approved its unaudited financial results for the quarter ended June 30, 2026, with an unmodified review report. The Board recommended the appointment of M/s Price Waterhouse Chartered Accountants LLP as statutory auditors for a 5-year term (FY27 to FY31) replacing BSR & Co. LLP. Additionally, the Board proposed an amendment to the Articles of Association allowing Temasek Group to nominate up to 3 directors and MGHS Group up to 2 directors, provided each holds at least 6% equity. The 16th Annual General Meeting is scheduled for September 29, 2026.
- Approved standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
- Appointed M/s Price Waterhouse Chartered Accountants LLP for a 5-year term from the 16th AGM (2026) to the 21st AGM (2031).
- Proposed AoA amendment granting Temasek Group up to 3 board seats and MGHS Group up to 2 seats, subject to maintaining a minimum 6% equity stake.
- Noted upside sharing arrangement between TPG and MRMSI dated March 16, 2026, requiring shareholder approval under SEBI Reg 26(6).
- Scheduled the 16th Annual General Meeting on Tuesday, September 29, 2026.
Manipal Health Enterprises Limited has signed a Business Transfer Agreement (BTA) to acquire the operations and assets of Kinder Women's Hospital in Whitefield, Bengaluru, for a cash consideration of ₹130 Crore. The hospital, commissioned in 2022, adds 100 beds to Manipal's existing presence in the Whitefield micro-market. The acquisition will expand Manipal's total footprint to over 13,500 licensed beds across 51 hospitals nationwide. The transaction does not involve share acquisition and is expected to close within 90 days subject to regulatory and customary approvals.
- Signed Business Transfer Agreement to acquire Kinder Women's Hospital for ₹130 Crores cash consideration.
- Adds 100 beds to network, expanding Manipal's pan-India capacity to over 13,500 licensed beds across 51 hospitals.
- Acquired hospital was recently commissioned in 2022 in the Whitefield (Doddanekundi) micro-market in Bengaluru.
- Transaction expected to close within 90 days, subject to statutory approvals and conditions precedent.
Manipal Health Enterprises Limited has entered into a Business Transfer Agreement to acquire the entire operations and assets of Kinder Women's Hospital and Fertility Centre in Bengaluru from Kindorama Healthcare Private Limited. The transaction is an all-cash asset acquisition valued at ₹130 crore. The target hospital operates a 100-bed facility and reported a turnover of ₹20.75 crore for the financial year ended March 31, 2026. The acquisition is slated for completion within 90 days, subject to statutory and customary approvals.
- Acquiring complete business operations and assets of Kinder Hospital for an all-cash consideration of ₹130 crore.
- Adds a 100-bed hospital capacity situated in Doddanekundi Industrial Area, Bengaluru.
- Target hospital recorded FY26 revenue from operations of ₹20.75 crore.
- Target facility was commissioned in 2022; transaction expected to close within 90 days.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
